buy

Regeneron Pharmaceuticals Inc. buy Morgan Stanley

Regeneron Pharmaceuticals Inc.

Start price

€692.50

/ 50%

Target price

04.08.24

Performance (%)

End price

€990.00

Summary

This prediction ended on with a price of €990.00. The BUY prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc. saw massive gains of . Morgan_Stanley has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Morgan_Stanley has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Feedback

Performance without dividends (%)

Name	1w	1m	1y
Regeneron Pharmaceuticals Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Morgan_Stanley for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 828.278

Change

Ends at

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Morgan Stanley from $897.00 to $912.00. They now have an "overweight" rating on the stock.

Ratings data for REGN provided by MarketBeat

Morgan Stanley